Your browser doesn't support javascript.
loading
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Wong, Selina K; Blum, Steven M; Sun, Xiaopeng; Da Silva, Inês P; Zubiri, Leyre; Ye, Fei; Bai, Kun; Zhang, Kevin; Ugurel, Selma; Zimmer, Lisa; Livingstone, Elisabeth; Schadendorf, Dirk; Serra-Bellver, Patricio; Muñoz-Couselo, Eva; Ortiz, Carolina; Lostes, Julia; Huertas, Roberto M; Arance, Ana; Pickering, Lisa; Long, Georgina V; Carlino, Matteo S; Buchbinder, Elizabeth I; Vázquez-Cortés, Leticia; Jara-Casas, Diego; Márquez-Rodas, Iván; González-Espinoza, Iván R; Balko, Justin M; Menzies, Alexander M; Sullivan, Ryan J; Johnson, Douglas B.
Afiliación
  • Wong SK; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Blum SM; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sun X; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Da Silva IP; University of Sydney, Melanoma Institute Australia, Sydney, Australia.
  • Zubiri L; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Bai K; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zhang K; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Ugurel S; University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Zimmer L; University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Livingstone E; University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Schadendorf D; University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Serra-Bellver P; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Muñoz-Couselo E; University Hospital Vall D'Hebron, Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Ortiz C; University Hospital Vall D'Hebron, Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Lostes J; University Hospital Vall D'Hebron, Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Huertas RM; Hospital Clinic de Barcelona, Barcelona, Spain.
  • Arance A; Hospital Clinic de Barcelona, Barcelona, Spain.
  • Pickering L; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Long GV; University of Sydney, Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Carlino MS; University of Sydney, Melanoma Institute Australia, Sydney, Australia; Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, Australia.
  • Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Vázquez-Cortés L; Clínica Médica ARCOS, Morelia, Mexico.
  • Jara-Casas D; University Hospital October 12, Madrid, Spain.
  • Márquez-Rodas I; Hospital General Universitario Gregorio Marañon, Madrid, Spain.
  • González-Espinoza IR; Hospital Ángeles Puebla, Puebla, Mexico.
  • Balko JM; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Menzies AM; University of Sydney, Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Sullivan RJ; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: Douglas.b.johnson@vumc.org.
Eur J Cancer ; 181: 188-197, 2023 03.
Article en En | MEDLINE | ID: mdl-36680880
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article